Charles Halpern Letter to ICOC
By Charles Halpern
| 09. 08. 2005
September 8, 2005
Dear Chairman Klein and Members of the Independent Citizen's Oversight Committee:
I reviewed the agenda for the September 9 ICOC meeting with interest and concern. My comments are addressed to Agenda Item 8, to the criteria for grants and for the procedure by which they have been processed. At this meeting, the ICOC should devote its time to genuine deliberation on the criteria for awarding grants-both training grants and research grants. The fact that these are Interim Criteria should not obscure the fact that the early rounds of grants will shape the Prop. 71 stem cell initiative for years to come. The criteria recommended by the Scientific and Medical Research Funding Working Group (WG), while a good starting point, are woefully incomplete. The ICOC should also reconfigure the process by which grant recommendations are presented to the ICOC in a manner which permits true deliberation on grant awards by the ICOC.
In particular, the ICOC should assure that none of the work in California laboratories and none of the training it funds will benefit those who...
Related Articles
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Staff, The Associated Press | 06.10.2025
PORTLAND, Ore. — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks...